Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Completed
AstraZeneca
Phase 3
2005-07-01
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is
more effective than placebo as a treatment for type 2 diabetic subjects who are not
sufficiently controlled with diet and exercise
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
Completed
AstraZeneca
Phase 3
2005-08-01
The purpose of this clinical research study is to learn whether Saxagliptin added to
Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic
subjects who are not sufficiently controlled with Metformin alone
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Completed
AstraZeneca
Phase 3
2006-05-01
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe
and works better than taking either saxagliptin or metformin alone
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Completed
Bristol-Myers Squibb
Phase 3
2007-12-01
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in
addition to metformin and compare to sulphonylurea in addition with metformin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
